New Alzheimer's drug repairs DNA damage and reduces brain inflammation
Researchers at King's College London have identified that an existing drug, KCL-286, shows promise in treating Alzheimer's disease by repairing DNA damage and reducing inflammation. The drug has already passed Phase 1 safety trials, potentially accelerating the development timeline for a disease-modifying therapy.
Why it matters
Current Alzheimer's treatments have limited efficacy; a drug targeting early-stage biological mechanisms could fundamentally change the prognosis for millions of patients.
Researchers at King's College London have identified a promising new strategy for tackling Alzheimer's disease by targeting several of the disease's earliest biological changes at the same time. Their study found that KCL-286, an experimental drug originally developed for spinal cord injury that has already passed Phase 1 safety trials, reduced multiple hallmarks of Alzheimer's in a mouse model.
"KCL-286 is a first-in-class, orally bioavailable small molecule that has already successfully cleared Phase 1 human safety and tolerability trials. This will dramatically cut down the traditional multi-year timeline required for new drug development," commented Professor Jonathan Corcoran, Professor of Neuroscience at the Institute of Psychiatry, Psychology & Neuroscience at King's College London.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in